Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shot up 2.5% on Thursday . The stock traded as high as $11.54 and last traded at $11.44, with a volume of 216,629 shares traded. The stock had previously closed at $11.16.

Several research firms recently weighed in on VNDA. Brean Capital restated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, April 27th. Jefferies Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Sunday, May 29th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.92.

The company has a 50-day moving average price of $11.17 and a 200 day moving average price of $9.22. The firm’s market capitalization is $483.75 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.07. During the same period in the prior year, the business earned ($0.10) EPS. The business had revenue of $33.30 million for the quarter, compared to analyst estimates of $32.48 million. The company’s revenue for the quarter was up 50.0% compared to the same quarter last year. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.83) EPS for the current year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. J. Goldman & Co LP raised its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals accounts for approximately 0.9% of J. Goldman & Co LP’s portfolio, making the stock its 25th largest position. J. Goldman & Co LP owned 2.11% of Vanda Pharmaceuticals worth $8,405,000 at the end of the most recent quarter.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.